Study Evaluating Magrolimab in Patients With TP53-Mutant AML Discontinued
Gilead has discontinued the ENHANCE-2 study, which was designed to evaluate magrolimab in AML patients with TP53 mutations.
Gilead has discontinued the ENHANCE-2 study, which was designed to evaluate magrolimab in AML patients with TP53 mutations.
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Bexmarilimab is a first-in-class, humanized monoclonal antibody designed to target Clever-1, a receptor on macrophages that leads to tumor growth and metastasis.
Survivors of common lymphoid neoplasms have an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia, data suggest.
Vanflyta is available only through a risk evaluation and mitigation strategy program.
Vanflyta is expected to be available in the coming weeks.
Higher spleen volume was tied to inferior outcomes for patients with AML undergoing hematopoietic stem cell transplant.
In recent years, outcomes have improved for AML patients undergoing unrelated or haploidentical transplant in second complete remission.
An all-oral triplet regimen is safe and effective in patients with newly diagnosed acute promyelocytic leukemia, a phase 2 trial suggests.
Processed red meat intake is associated with an increased incidence of AML and MDS in a Japanese population, a study suggests.